141 related articles for article (PubMed ID: 3264781)
21. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
22. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus.
Yang PT; Kasai H; Zhao LJ; Xiao WG; Tanabe F; Ito M
Clin Exp Immunol; 2004 Nov; 138(2):342-7. PubMed ID: 15498047
[TBL] [Abstract][Full Text] [Related]
23. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus.
ter Borg EJ; Horst G; Limburg PC; Kallenberg CG
Clin Exp Immunol; 1990 Oct; 82(1):21-6. PubMed ID: 2208793
[TBL] [Abstract][Full Text] [Related]
24. The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
Dooley MA; Cush JJ; Lipsky PE; Dawson DV; Pisetsky DS
J Rheumatol; 1993 Nov; 20(11):1857-62. PubMed ID: 8308770
[TBL] [Abstract][Full Text] [Related]
25. Diminished IL-17A levels may protect filarial-infected individuals from development of rheumatoid arthritis and systemic lupus erythematosus.
Panda AK; Das BK
Lupus; 2017 Apr; 26(4):348-354. PubMed ID: 27488471
[TBL] [Abstract][Full Text] [Related]
26. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
[TBL] [Abstract][Full Text] [Related]
27. Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus.
Holcombe RF; Baethge BA; Wolf RE; Betzing KW; Stewart RM; Hall VC; Fukuda M
Lupus; 1994 Apr; 3(2):97-102. PubMed ID: 7920621
[TBL] [Abstract][Full Text] [Related]
28. Phagocytosis, bactericidal capacity, and PGE2 production of monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Cruchaud A; Despont JP; Roth A; Dayer JM
Diagn Immunol; 1984; 2(4):203-12. PubMed ID: 6597049
[TBL] [Abstract][Full Text] [Related]
29. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
[TBL] [Abstract][Full Text] [Related]
30. Increased soluble IL-2 receptor in serum of patients with systemic lupus erythematosus.
Sawada S; Hashimoto H; Iijma S; Tokano Y; Matsukawa Y; Takei M; Ishikawa H; Kang H; Tomura K; Mitamura K
Clin Rheumatol; 1993 Jun; 12(2):204-9. PubMed ID: 8358979
[TBL] [Abstract][Full Text] [Related]
31. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy.
Damián-Abrego GN; Cabiedes J; Cabral AR
Lupus; 2008 Apr; 17(4):300-4. PubMed ID: 18413411
[TBL] [Abstract][Full Text] [Related]
32. Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.
Itoh M; Goto Y; Ohta Y; Goto Y; Ohashi H
Clin Rheumatol; 1998; 17(1):26-30. PubMed ID: 9586675
[TBL] [Abstract][Full Text] [Related]
33. Soluble interleukin-2 receptor levels in lupus nephritis.
Laut J; Senitzer D; Petrucci R; Sablay LB; Barland P; Glicklich D
Clin Nephrol; 1992 Oct; 38(4):179-84. PubMed ID: 1424303
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus.
Narumi S; Takeuchi T; Kobayashi Y; Konishi K
Cytokine; 2000 Oct; 12(10):1561-5. PubMed ID: 11023674
[TBL] [Abstract][Full Text] [Related]
35. Lack of association between hyperprolactinemia and soluble IL-2 receptor levels in systemic lupus erythematosus.
Daza L; Lavalle C; Duarte C; Huerta R; Moreno J
Lupus; 2003; 12(2):107-11. PubMed ID: 12630754
[TBL] [Abstract][Full Text] [Related]
36. Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice.
Balderas RS; Josimovic-Alasevic O; Diamantstein T; Dixon FJ; Theofilopoulos AN
J Immunol; 1987 Sep; 139(5):1496-500. PubMed ID: 3114368
[TBL] [Abstract][Full Text] [Related]
37. Soluble interleukin-2 receptors in systemic lupus erythematosus.
Wolf RE; Brelsford WG
Arthritis Rheum; 1988 Jun; 31(6):729-35. PubMed ID: 3132927
[TBL] [Abstract][Full Text] [Related]
38. [The content of interleukin-1 beta in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis].
Ketlinskiĭ SA; Alekseeva TG; Perumov ND; Simbirtsev AS
Ter Arkh; 1993; 65(12):51-4. PubMed ID: 8146772
[TBL] [Abstract][Full Text] [Related]
39. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus.
Qing YF; Zhang QB; Zhou JG; Yuan GH; Wei J; Xing Y; Liu JP; Jiang L; Chen JP
Lupus; 2009 Jul; 18(8):713-7. PubMed ID: 19502267
[TBL] [Abstract][Full Text] [Related]
40. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
